Ceramide: A common pathway for atherosclerosis?

Atherosclerosis

Volumn 196, Issue 2, 2008, Pages 497-504

  Bismuth, Jean ^a   Lin, Peter ^a   Yao, Qizhi ^a   Chen, Changyi ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; C reactive protein; Ceramide; Homocysteine; Lipids

Indexed keywords

CERAMIDE; CYTOKINE; HOMOCYSTEINE; LIPID; LIPOPROTEIN; MATRIX METALLOPROTEINASE; NITRIC OXIDE; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; SPHINGOMYELIN PHOSPHODIESTERASE; THERMOZYMOCIDIN; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW;

ATHEROSCLEROSIS; CERAMIDES; FATTY ACIDS, MONOUNSATURATED; HOMOCYSTEINE; HUMANS; MATRIX METALLOPROTEINASES; NITRIC OXIDE; REACTIVE OXYGEN SPECIES; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38349092384     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.09.018     Document Type: Review

References (92)

1. Jiang X.C., Paultre F., Pearson T.A., et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 20 (2000) 2614-2618
2. Schissel S.L., Tweedie-Hardman J., Rapp J.H., et al. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest 98 (1996) 1455-1464
3. Li Z., Basterr M.J., Hailemariam T.K., et al. The effect of dietary sphingolipids on plasma sphingomyelin metabolism and atherosclerosis. Biochim Biophys Acta 1735 (2005) 130-134
4. Tabas I., Li Y., Brocia R.W., et al. Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation. J Biol Chem 268 (1993) 20419-20432
5. Schissel S.L., Jiang X., Tweedie-Hardman J., et al. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J Biol Chem 273 (1998) 2738-2746
6. Xu X.X., and Tabas I. Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages. J Biol Chem 266 (1991) 24849-24858
7. Kolesnick R.N. Sphingomyelin and derivatives as cellular signals. Prog Lipid Res 30 (1991) 1-38
8. Spiegel S., and Merrill Jr. A.H. Sphingolipid metabolism and cell growth regulation. FASEB J 10 (1996) 1388-1397
9. Merrill Jr. A.H., Schmelz E.M., Dillehay D.L., et al. Sphingolipids-the enigmatic lipid class: biochemistry, physiology, and pathophysiology. Toxicol Appl Pharmacol 142 (1997) 208-225
10. Marchesini N., and Hannun Y.A. Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochem Cell Biol 82 (2004) 27-44
11. Futerman A.H., and van Meer G. The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 5 (2004) 554-565
12. Jeong T., Schissel S.L., Tabas I., et al. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J Clin Invest 101 (1998) 905-912
13. Hoff H.F., and Morton R.E. Lipoproteins containing apo B extracted from human aortas. Structure and function. Ann N Y Acad Sci 454 (1985) 183-194
14. Chatterjee S. Sphingolipids in atherosclerosis and vascular biology. Arterioscler Thromb Vasc Biol 18 (1998) 1523-1533
15. Chatterjee S., and Kwiterovich P.O. Glycosphingolipids of human plasma lipoproteins. Lipids 11 (1976) 462-466
16. Dawson G., Kruski A.W., and Scanu A.M. Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res 17 (1976) 125-131
17. Prokazova N.V., Mukhin D.N., Orekhov A.N., et al. Neutral glycolipids of atherosclerotic plaques and unaffected human aorta tissue. Eur J Biochem 180 (1989) 167-171
18. Ichi I., Nakahara K., Kiso K., and Kojo S. Effect of dietary cholesterol and high fat on ceramide concentration in rat tissues. Nutrition 23 (2007) 570-574
19. Grandl M., Bared S.M., Liebisch G., et al. E-LDL and Ox-LDL differentially regulate ceramide and cholesterol raft microdomains in human macrophages. Cytometry A 69 (2006) 189-191
20. Arimoto I., Saito H., Kawashima Y., et al. Effects of sphingomyelin and cholesterol on lipoprotein lipase-mediated lipolysis in lipid emulsions. J Lipid Res 39 (1998) 143-151
21. Bhagat K., and Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 96 (1997) 3042-3047
22. Nakamura M., Yoshida H., Arakawa N., et al. Effects of tumor necrosis factor-alpha on basal and stimulated endothelium-dependent vasomotion in human resistance vessel. J Cardiovasc Pharmacol 36 (2000) 487-492
23. Wang P., Ba Z.F., and Chaudry I.H. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol 266 (1994) H2535-H2541
24. Xu J., Yeh C.H., Chen S., et al. Involvement of de novo ceramide biosynthesis in tumor necrosis factor-alpha/cycloheximide-induced cerebral endothelial cell death. J Biol Chem 273 (1998) 16521-16526
25. Modur V., Zimmerman G.A., Prescott S.M., and McIntyre T.M. Endothelial cell inflammatory responses to tumor necrosis factor alpha. Ceramide-dependent and -independent mitogen-activated protein kinase cascades. J Biol Chem 271 (1996) 13094-13102
26. Sawada M., Kiyono T., Nakashima S., et al. Molecular mechanisms of TNF-alpha-induced ceramide formation in human glioma cells: P53-mediated oxidant stress-dependent and -independent pathways. Cell Death Differ 11 (2004) 997-1008
27. Hannun Y.A. Functions of ceramide in coordinating cellular responses to stress. Science 274 (1996) 1855-1859
28. Liu B., Andrieu-Abadie N., Levade T., et al. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J Biol Chem 273 (1998) 11313-11320
29. Singh I., Pahan K., Khan M., and Singh A.K. Cytokine-mediated induction of ceramide production is redox-sensitive. J Biol Chem 273 (1998) 20354-20362
30. Garcia-Ruiz C., Colell A., Mari M., et al. Direct effects of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species. J Biol Chem 272 (1997) 11369-11377
31. Zhang D.X., Zou A.P., and Li P.L. Ceramide-induced activation of NADPH oxidase and endothelial dysfunction in small coronary arteries. Am J Physiol Heart Circ Physiol 284 (2003) H605-H612
32. Zhang D.X., Fryer R.M., Hsu A.K., et al. Production and metabolism of ceramide in normal and ischemic-reperfused myocardium of rats. Basic Res Cardiol 96 (2001) 267-274
33. Memon R.A., Bass N.M., Moser A.H., et al. Down-regulation of liver and heart specific fatty acid binding proteins by endotoxin and cytokines in vivo. Biochim Biophys Acta 1440 (1999) 118-126
34. Blake G.J., and Ridker P.M. Novel clinical markers of vascular wall inflammation. Circ Res 89 (2001) 763-771
35. Hirokawa M., Kitabayashi A., Kuroki J., and Miura A.B. Induction of tissue factor production but not the upregulation of adhesion molecule expression by ceramide in human vascular endothelial cells. Tohoku J Exp Med 191 (2000) 167-176
36. Gu Q., Yang X.P., Bonde P., et al. Inhibition of TNF-alpha reduces myocardial injury and proinflammatory pathways following ischemia-reperfusion in the dog. J Cardiovasc Pharmacol 48 (2006) 320-328
37. Siragy H.M., Xue C., and Webb R.L. Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-alpha production after cardiac ischemia. J Cardiovasc Pharmacol 47 (2006) 636-642
38. Csiszar A., Labinskyy N., Smith K., et al. Vasculoprotective effects of anti-tumor necrosis factor-{alpha} treatment in aging. Am J Path 170 (2007) 388-398
39. Csiszar A., Smith K., Labinskyy N., et al. Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: role of NF-kappaB inhibition. Am J Physiol Heart Circ Physiol 291 (2006) H1694-H1699
40. Ito H., Koide N., Hassan F., et al. Lethal endotoxic shock using alpha-galactosylceramide sensitization as a new experimental model of septic shock. Lab Invest 86 (2006) 254-261
41. Hürlimann D., Forster A., Noll G., et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106 (2002) 2184-2187
42. Booth A.D., Jayne D.R., Kharbanda R.K., et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 109 (2004) 1718-1723
43. Graham I.M., Daly L.E., Refsum H.M., et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 277 (1997) 1775-1781
44. Taylor Jr. L.M., Moneta G.L., Sexton G.J., et al. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 29 (1999) 8-19
45. Yang Z.Z., and Zou A.P. Homocysteine enhances TIMP-1 expression and cell proliferation associated with NADH oxidase in rat mesangial cells. Kidney Int 63 (2003) 1012-1020
46. Yi F., Zhang A.Y., Janscha J.L., et al. Homocysteine activates NADH/NADPH oxidase through ceramide-stimulated Rac GTPase activity in rat mesangial cells. Kidney Int 66 (2004) 1977-1987
47. Yi F., Zhang A.Y., Li N., et al. Inhibition of ceramide-redox signaling pathway blocks glomerular injury in hyperhomocysteinemic rats. Kidney Int 70 (2006) 88-96
48. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90 (2002) 251-262
49. Ikeda U., and Shimada K. Matrix metalloproteinases and coronary artery diseases. Clin Cardiol 26 (2003) 55-59
50. Lijnen H.R. Extracellular proteolysis in the development and progression of atherosclerosis. Biochem Soc Trans 30 (2002) 163-167
51. Xu X.P., Meisel S.R., Ong J.M., et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 99 (1999) 993-998
52. Rajavashisth T.B., Liao J.K., Galis Z.S., et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem 274 April (1999) 11924-11929
53. Huang Y., Song L., Wu S., et al. Oxidized LDL differentially regulates MMP-1 and TIMP-1 expression in vascular endothelial cells. Atherosclerosis 156 (2001) 119-125
54. Auge N., Maupas-Schwalm F., Elbaz M., et al. Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation. Circulation 110 (2004) 571-578
55. Izgi C., Cevik C., Ozkan M., et al. Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation. Circulation 111 (2005) e38-e39
56. Huwiler A., Kolter T., Pfeilschifter J., and Sandhoff K. Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta 31 1485 (2000) 63-99
57. Hernandez O.M., Discher D.J., Bishopric N.H., and Webster K. Rapid activation of neutral sphingomyelinase by hypoxia-reoxygenation of cardiac myocytes. Circ Res 86 (2000) 198-204
58. Li H., Junk P., Huwiler A., et al. Dual effect of ceramide on human endothelial cells: induction of oxidative stress and transcriptional upregulation of endothelial nitric oxide synthase. Circulation 106 (2002) 2250-2256
59. Yeh L.H., Kinsey A.M., Chatterjee S., and Alevriadou B.R. Lactosylceramide mediates shear-induced endothelial superoxide production and intercellular adhesion molecule-1 expression. J Vas Res 38 (2001) 551-559
60. Williams R.D., Wang E., and Merrill Jr. A.H. Enzymology of long-chain base synthesis by liver: characterization of serine palmitoyltransferase in rat liver microsomes. Arch Biochem Biophys 228 (1984) 282-291
61. Pchejetski D., Kunduzova O., Dayon A., et al. Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ Res 100 (2007) 41-49
62. Bielawska A.E., Shapiro J.P., Jiang L., et al. Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. Am J Path 151 (1997) 1257-1263
63. Bandyopadhyay D., Chattopadhyay A., Ghosh G., and Datta A.G. Oxidative stress-induced ischemic heart disease: protection by antioxidants. Cur Med Chem 11 (2004) 369-387
64. Bolli R. Basic and clinical aspects of myocardial stunning. Prog Cardiovasc Dis 40 (1998) 477-516
65. Kunduzova O.R., Bianchi P., Parini A., and Cambon C. Hydrogen peroxide production by monoamine oxidase during ischemia/reperfusion. Eur J Pharm 448 (2002) 225-230
66. Spiegel S., and Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nature Rev 4 (2003) 397-407
67. Karliner J.S., Honbo N., Summers K., et al. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol 33 (2001) 1713-1717
68. Olivera A., Kohama T., Edsall L., et al. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J Cell Biol 147 (1999) 545-558
69. Jin Z.Q., Goetzl E.J., and Karliner J.S. Sphingosine kinase activation mediates ischemic preconditioning in murine heart. Circulation 110 (2004) 1980-1989
70. Zhang D.X., Zou A.P., and Li P.L. Ceramide reduces endothelium-dependent vasodilation by increasing superoxide production in small bovine coronary arteries. Circ Res 88 (2001) 824-831
71. Mogami K., Kishi H., and Kobayashi S. Sphingomyelinase causes endothelium-dependent vasorelaxation through endothelial nitric oxide production without cytosolic Ca(2+) elevation. FEBS Lett 579 (2005) 393-397
72. Igarashi J., Thatte H.S., Prabhakar P., Golan D.E., and Michel T. Calcium-independent activation of endothelial nitric oxide synthase by ceramide. Proc Natl Acad Sci U S A 96 (1999) 12583-12588
73. Bulotta S., Barsacchi R., Rotiroti D., et al. Activation of the endothelial nitric-oxide synthase by tumor necrosis factor-α. A novel feedback mechanism regulating cell death. J Biol Chem 276 (2001) 6529-6536
74. Igarashi J., Thatte H.S., Prabhakar P., et al. Calcium-independent activation of endothelial nitric oxide synthase by ceramide. Proc Natl Acad Sci U S A 96 (1999) 12583-12588
75. Bhunia A.K., Han H., Snowden A., and Chatterjee S. Redox-regulated signaling by lactosylceramide in the proliferation of human aortic smooth muscle cells. J Biol Chem 272 (1997) 15642-15649
76. Harada-Shiba M., Kinoshita M., Kamido H., and Shimokado K. Oxidized low density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms. J Biol Chem 273 (1998) 9681-9687
77. Hein T.W., and Kuo L. LDLs impair vasomotor function of the coronary microcirculation: role of superoxide anions. Circ Res 83 (1998) 404-414
78. Merrill Jr. A.H., Wang E., Stevens J., and Brumley G.W. Activities of the initial enzymes of glycerolipid and sphingolipid synthesis in lung microsomes from rats exposed to air or 85% oxygen. Biochem Biophys Res Commun 119 (1984) 995-1000
79. Williams R.D., Sgoutas D.S., and Zaatari G.S. Enzymology of long-chain base synthesis by aorta: induction of serine palmitoyltransferase activity in rabbit aorta during atherogenesis. J Lipid Res 27 (1986) 763-770
80. Fujita T., Inoue K., Yamamoto S., et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiotics 47 (1994) 208-215
81. Chen J.K., Lane W.S., and Schreiber S.L. The identification of myriocin-binding proteins. Chem Biol 6 (1999) 221-235
82. Park T.S., Panek R.L., Mueller S.B., et al. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 110 (2004) 3465-3471
83. Park T.S., Panek R.L., Rekhter M.D., et al. Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice. Atherosclerosis 189 (2006) 264-272
84. Hojjati M.R., Li Z., Zhou H., et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem 280 (2005) 10284-10289
85. Nordestgaard B.G., Gronholdt M.L., and Sillesen H. Echolucent rupture-prone plaques. Curr Opin Lipidol 14 (2003) 505-512
86. Tabas I. Sphingolipids and atherosclerosis: a mechanistic connection? A therapeutic opportunity?. Circulation 110 (2004) 3400-3401
87. Li J.J., Zheng X., and Li J. Statins may be beneficial for patients with slow coronary flow syndrome due to its anti-inflammatory property. Med Hypotheses 69 (2007) 333-337
88. Osto E., Coppolino G., Volpe M., and Cosentino F. Restoring the dysfunctional endothelium. Curr Pharm Des 13 (2007) 1053-1068
89. Chen S.D., Hu C.J., Yang D.I., et al. Pravastatin attenuates ceramide-induced cytotoxicity in mouse cerebral endothelial cells with HIF-1 activation and VEGF upregulation. Ann N Y Acad Sci 1042 (2005) 357-364
90. Mathias S., Pena L.A., and Kolesnick R.N. Signal transduction of stress via ceramide. Biochem J 335 (1998) 465-480
91. Brenner B., Koppenhoefer U., Weinstock C., et al. Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. J Biol Chem 272 (1997) 22173-22181
92. Shabahang S., Liu Y.H., Huwiler A., and Pfeilschifter J. Identification of the LIM kinase-1 as a ceramide-regulated gene in renal mesangial cells. Biochem Biophys Res Commun 298 (2002) 408-413